#USA #New York #Securities Fraud #Pomerantz LLP #Cellectis

Investor Alert: Investigation into Cellectis S.A. by Pomerantz Law Firm

The Pomerantz Law Firm has initiated an investigation regarding potential claims on behalf of the investors of Cellectis S.A. (CLLS), a company listed on NASDAQ. Following recent concerning announcements by Cellectis, investors might be affected by significant losses, leading to potential legal actions.

Background

On September 14, 2026, Cellectis made a pivotal announcement indicating a strategic shift toward prioritizing in vivo gene editing therapies, specifically HEAL-101 and HEAL-201, over its previously pursued CAR-T cell therapies, namely lasme-cel and eti-cel. The implications of this decision are monumental, not only for the company's future developments but also for those who have invested in these therapies anticipating substantial returns.

During a conference call, Cellectis' Chief Medical Officer, Adrian Kilcoyne, expressed the company's inability to fund these CAR-T cell therapies due to pressing timelines and limited financial resources. This stark revelation understandably raised concerns among investors about the direction and stability of the company, culminating in a significant drop in share value.

Impact on Share Price

In the wake of the announcement, Cellectis’s American Depositary Receipt (ADR) witnessed a dramatic decline of 40.97%, falling from $3.10 to $1.83 per ADR on that very day. Such a steep decrease signifies the immediate market reaction to the strategic shift and may indicate deeper issues regarding the company's financial health and management decisions. This scenario has prompted Pomerantz LLP to investigate allegations of securities fraud or any unlawful business practices potentially linked to Cellectis and its executives.

The Law Firm's Role

Pomerantz LLP is renowned for its expertise in corporate, securities, and antitrust class litigation. With over 85 years of history in defending the rights of investors and fighting against corporate malfeasance, the firm aims to ensure accountability and justice for investors affected by Cellectis's significant disclosure.

Danielle Peyton of Pomerantz has encouraged any investors who feel they have suffered losses due to these developments to reach out directly through their established communication channels. The firm is keen on gathering information to support any potential class action lawsuit that could arise due to the alleged misconduct.

Affected investors are advised to contact Danielle Peyton at [email protected] or call 646-581-9980, ext. 7980 for confidential support.

Conclusion

With major legal implications surrounding Cellectis S.A., investors are urged to stay informed and participate in seeking justice for their investments. The investigation by Pomerantz Law Firm highlights the importance of corporate transparency and accountability in the biotech sector, an industry that is especially volatile and sensitive to public disclosures and market perceptions. Keeping an eye on future developments from both Cellectis and Pomerantz will be critical for investors moving forward.